CK 0801

Drug Profile

CK 0801

Alternative Names: CK0801

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellenkos; University of Texas M. D. Anderson Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Graft-versus-host disease
  • Preclinical Aplastic anaemia; Autoimmune disorders; Multiple sclerosis; Psoriasis; Type 1 diabetes mellitus

Most Recent Events

  • 01 Dec 2017 Phase-I clinical trials in Graft-versus-host disease in USA (IV) before December 2017
  • 01 Dec 2017 Preclinical trials in Aplastic anaemia in USA (IV) before December 2017
  • 01 Dec 2017 Preclinical trials in Multiple sclerosis in USA (IV) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top